Lergonix

Bilastine, the active ingredient in Lergonix, is a second‑generation H1 antihistamine presented as an oral tablet for oral use. It is employed to relieve symptoms of allergic rhinitis and chronic idiopathic urticaria in adults and adolescents, providing effective antiallergic control through selective peripheral H1‑receptor antagonism.

GNH USA supplies Lergonix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide with rigorous quality assurance and regulatory conformance. The company ensures consistent product availability and compliance with EU pharmacopeial standards.

Bilastine is a second‑generation H1 antihistamine that addresses allergic conditions affecting the nasal passages and skin.

- Allergic rhinitis: reduces nasal congestion, sneezing, itching and rhinorrhea. - Seasonal allergic rhinitis: controls symptoms triggered by seasonal pollen exposure. - Perennial allergic rhinitis: alleviates year‑round nasal allergy manifestations. - Chronic idiopathic urticaria: diminishes wheals and itching associated with chronic hives.

Bilastine is generally well tolerated, but some patients may experience adverse reactions.

Common Side Effects: - Headache: mild to moderate headache reported. - Dry mouth: sensation of oral dryness. - Nausea: occasional stomach upset.

Serious or Rare Side Effects: - Anaphylactic reaction: rare severe allergic response. - Stevens‑Johnson syndrome: rare severe skin eruption. - Angioedema: swelling of face, lips or tongue.

Before using Lergonix, consider the following precautions to ensure safe therapy.

- Pregnancy: safety not established; consult a healthcare professional before use. - Breastfeeding: unknown risk; weigh benefits against potential effects on the infant. - Renal impairment: dosage may need adjustment in patients with reduced kidney function. - Concomitant CYP inhibitors: avoid strong CYP3A4 inhibitors that can raise bilastine levels. - Elderly: monitor for increased sedation or dizziness. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Bilastine may interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Ketoconazole: strong CYP3A4 inhibition can markedly increase bilastine exposure. - Erythromycin: may raise plasma concentrations of bilastine. - Ritonavir: potent CYP3A4 inhibitor that can elevate bilastine levels.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive sedative effect may occur. - Alcohol: may enhance drowsiness when combined with bilastine.